A. Schoenfeld

Oncology · 2020

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Schoenfeld trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. S. Spranger
  2. C. Robert
  3. T. Gajewski
  4. E. Trombetta
  5. William Pao

Papers from A. Schoenfeld's perspective

Ordered by how strongly the researchers A. Schoenfeld trusts endorse each paper. Same corpus, a different order for every researcher.

  1. PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
  2. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell)
  3. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  4. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma (New England Journal of Medicine)
  5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  6. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  7. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (Science)
  8. Loss of PTEN promotes resistance to T cell-mediated immunotherapy (Cancer Discovery)
  9. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade (Science)
  10. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (Cancer Discovery)

Their papers